Clinical trial
Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis.
To investigate the ability of the HAP score to accurately predict responders to Octagam 5%
| Category | Value |
|---|---|
| Study start date | 2013-07-01 |